Great Lakes Advisors LLC reduced its position in shares of Bio-Rad Laboratories Inc. (NYSE:BIO) by 28.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 41,389 shares of the company’s stock after selling 16,157 shares during the period. Great Lakes Advisors LLC owned 0.14% of Bio-Rad Laboratories worth $6,780,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Advisors Asset Management Inc. raised its stake in shares of Bio-Rad Laboratories by 22.3% in the second quarter. Advisors Asset Management Inc. now owns 734 shares of the company’s stock worth $105,000 after buying an additional 134 shares during the last quarter. Advisor Group Inc. purchased a new stake in shares of Bio-Rad Laboratories during the second quarter worth $108,000. Barclays PLC raised its stake in shares of Bio-Rad Laboratories by 48.8% in the second quarter. Barclays PLC now owns 1,052 shares of the company’s stock worth $149,000 after buying an additional 345 shares during the last quarter. Creative Planning raised its stake in shares of Bio-Rad Laboratories by 14.0% in the third quarter. Creative Planning now owns 1,007 shares of the company’s stock worth $165,000 after buying an additional 124 shares during the last quarter. Finally, Cantab Capital Partners LLP raised its stake in shares of Bio-Rad Laboratories by 72.0% in the second quarter. Cantab Capital Partners LLP now owns 1,300 shares of the company’s stock worth $186,000 after buying an additional 544 shares during the last quarter. Institutional investors and hedge funds own 64.17% of the company’s stock.

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Shares of Bio-Rad Laboratories Inc. (NYSE:BIO) traded down 0.42% during midday trading on Wednesday, reaching $173.55. 94,014 shares of the company traded hands. The firm has a market capitalization of $5.13 billion, a P/E ratio of 52.21 and a beta of 0.88. Bio-Rad Laboratories Inc. has a 12 month low of $122.03 and a 12 month high of $174.77. The company has a 50 day moving average of $165.56 and a 200 day moving average of $153.87.

Bio-Rad Laboratories (NYSE:BIO) last issued its quarterly earnings results on Tuesday, November 1st. The company reported $0.62 EPS for the quarter, topping the consensus estimate of $0.51 by $0.11. Bio-Rad Laboratories had a net margin of 4.75% and a return on equity of 3.79%. The firm earned $508.75 million during the quarter, compared to analyst estimates of $480.60 million. During the same quarter in the prior year, the business posted $0.59 earnings per share. Bio-Rad Laboratories’s revenue for the quarter was up 8.3% compared to the same quarter last year. On average, equities research analysts predict that Bio-Rad Laboratories Inc. will post $2.77 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This news story was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another site, it was illegally copied and reposted in violation of international trademark & copyright law. The original version of this news story can be viewed at https://www.thecerbatgem.com/2016/11/30/great-lakes-advisors-llc-has-6780000-position-in-bio-rad-laboratories-inc-bio.html.

A number of equities research analysts have recently weighed in on BIO shares. CL King started coverage on shares of Bio-Rad Laboratories in a report on Wednesday, October 12th. They issued a “buy” rating and a $180.00 price objective on the stock. Jefferies Group raised their price objective on shares of Bio-Rad Laboratories from $200.00 to $225.00 and gave the company a “buy” rating in a report on Wednesday, September 7th. Finally, Zacks Investment Research upgraded shares of Bio-Rad Laboratories from a “strong sell” rating to a “hold” rating in a report on Tuesday, November 8th.

In other Bio-Rad Laboratories news, VP James R. Stark sold 1,299 shares of the business’s stock in a transaction that occurred on Wednesday, November 9th. The shares were sold at an average price of $171.42, for a total transaction of $222,674.58. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 28.38% of the company’s stock.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of life science research and clinical diagnostics products. The Company manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

5 Day Chart for NYSE:BIO

Receive News & Stock Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related stocks with our FREE daily email newsletter.